MAIA

$1.33-$0.04 (-2.90%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$83.9M

61M shares

52-week range

$0.87 – $3.19

20% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

XASE

Change$-3.12

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$65M	+83.6%	$-0.52	$-0.52–$-0.52	—	1
2027	$66M	+2.0%	$1.12	$1.12–$1.12	1.2×	1
2028	$402M	+506.8%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-10	$-0.11	$-0.13	-18.2%
2026-05-11	$-0.18	$-0.14	+22.2%
2026-03-23	$-0.13	$-0.08	+38.5%
2025-11-07	$-0.19	$-0.27	-42.1%
2025-08-11	$-0.24	$-0.18	+25.0%
2025-05-09	$-0.18	$-0.16	+11.1%
2025-03-21	$-0.20	$-0.17	+15.0%
2024-11-12	$-0.32	$-0.11	+65.6%

MAIA Biotechnology, Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

www.maiabiotech.com

Employees: 13
IPO / List date: Jul 28, 2022
HQ: CHICAGO, IL

Held by traders on TradeandTell

No one on the platform currently holds MAIA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in MAIA as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded MAIA yet.

$MAIA chatter on StockTwits

Aj Modi, MD@aj_2d
$MAIA Vitoc promised a partner, there are no partners. Let’s go Vlad wake the fark up
View on StockTwits ↗
Jay@MoneyHelixBullish3d
$MAIA Fantastic financial performance! I was expecting more cash to be burning, but MAIA kept it at a well-controlled $6.7M for Q2! The interest income and grant income reduced net expenses by almost 6%! MAIA is still diluting a little bit using stock-based compensation, but it's relatively minor at 1.6M shares given out in 6 months. MAIA has enough cash to make it to the end of Q2 2027, which is another 10 months from today. CEO Vitoc is gonna line up the next round of investors at JPMHCC / BSC 2027 and will be ready to pitch then one hell of a slide deck! 🥂
View on StockTwits ↗
MARK A@DiamondDog333d
$MAIA TRYING TO FIGURE OUT WHERE THINGS ARE BURIED IN THE Q REPORT IS LIKE READING CHINESE.... From Warrants to Bitcoin to Conversions to Admn /trial exp....ITS a MAZE one thing is for sure ....the DOUBLING OF SHARES to NEAR 61 mil from 30 mil yet still not much cash is pretty evident.. OVERVALUED SLUG and BURN increased substantially and I LOVE THE BONUSES GRANTED <<<<<<<LOL LOL LOL LOL LOL LOL nice buy sub 1
View on StockTwits ↗
Steve@ChemasterBullish3d
$MAIA Three deep dive models reviewed today's financials and indicate plenty of cash till mid to late 2027 well beyond Phase 3 intermim data. I realize this is AI but all three resulted in similar results with each satisfying my expectations. Cash position is adequate to reach key clinical milestones, including potential completion of Phase 2 interim/efficacy data and into the expected Phase 3 interim analysis window in 2027, without needing immediate new cash. Key financials (Q2 2026 10-Q, ended June 30, 2026) Cash: $27.6 million (vs. $8.7 million at year-end 2025), boosted by the ~$33 million gross (~$31 million net) March 2026 equity offering. Working capital: ~$22.0 million; current liabilities ~$6.3 million; no debt. Net loss: Q2 ~$7.9 million; H1 ~$14.3 million. Operating expenses: Q2 ~$8.3 million (R&D ~$5.6 million driven by trial expansion); H1 ~$15.3 million. Operating cash burn (H1 2026): ~$12.1 million (~$2.0 million/month average). Q2 burn ran higher than Q1 as clinical activity increased. At the recent ~$24 million annualized operating cash burn rate, the $27.6 million cash supports roughly 12–14+ months of runway from June 30, 2026 (into roughly Q3–Q4 2027). If burn accelerates further with enrollment, it could compress toward ~12 months; modest interest/grant income provides a small offset. The company states the March proceeds are expected to fully fund the ongoing pivotal Phase 3 and that additional capital will ultimately be needed for operations and commercialization.
View on StockTwits ↗
DN@DAWGNuts3d
$MAIA when do they release financials? I thought it was today PMlre Market?
View on StockTwits ↗
Mut@NoFooling5d
$MAIA Hey Group, I am new here. Can someone please provide information to bring me upto speed eg MAIA Cataysts Timeline? Short term & Long Term expectations? I'm in love with OSTX & BCTX; how does MAIA stack up compared to BCTX & OSTX? THANK YOU!!!]
View on StockTwits ↗
Nhien LH@StergDaddy1016d
$MAIA I will be in this hot chick at the end of this year!!!
View on StockTwits ↗
ShadowSnake@ShadowSnake6d
$MAIA been holding this turd since 2022.. will this do anything anytime soon? 😔
View on StockTwits ↗
Pete lamb@stu4Aug 6
$MAIA True August for Biotechs, is dull Unless bought out !! As XLRN !!!
View on StockTwits ↗
MARK A@DiamondDog33Aug 6
$MAIA time for a promo
View on StockTwits ↗
Jay@MoneyHelixBullishAug 5
$MAIA Next financing event for MAIA will likely be during or after JPMHCC and Biotech Showcase in January 2027. MAIA has a pattern of releasing lots of news in December leading into the January showcase. When MAIA was low on cash, they would raise small sums prior to the showcase to stay afloat, but they don't need to do that anymore. At the next JPMHCC and Biotech Showcase, MAIA's team will be going to investors and Big Pharma decision-makers telling them about the incoming interim results and accelerated approval potential. It could quickly spiral into talks of a buyout or partnership if CEO Vitoc has positive news to release leading into JPMHCC and BSC 🥂
View on StockTwits ↗
Lip Ripper@RippinlipsAug 5
$MAIA I like this under the radar rise over the last week. Very low volume, when this goes, it’s going to explode. Also nice to D Dog not pissing and shitting all over the thread lately.
View on StockTwits ↗
Steve@ChemasterBullishAug 5
$MAIA Please explain your logic. I think with the receipt 33M investment they have plenty of cash for at least mid 2027 and after interim results.
View on StockTwits ↗
LabPsycho@LabPsychoAug 5
$MAIA @jcmeredith1 I am expecting another raise by say December. I hope it is based on good data or partnership or something of substance rather than these road show gimmicks and promo videos / Noble type things. Raise based on data or paying partnership please. Good luck
View on StockTwits ↗
John Meredith@jcmeredith1Aug 5
$MAIA @LabPsycho @Kosmokrat @telomerase @MoneyHelix @Chemaster I’m thinking that we will get more positive interim data before they put together another capital raise. The next OS number for these 3L patients could be significant. The next DCR number for these same 3L patients could be equally significant. No one else is going after cancer cell telomeres. The patent cliff has not disappeared.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.